Coherus BioSciences (NASDAQ:CHRS – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $13.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 496.33% from the company’s current […]
Related Keywords
United States , America , Dennism Lanfear , Coherus Biosciences , Robertw Baird , Coherus Biosciences Company Profile , Hermes Inc , Dorsey Whitney Trust , Maxim Group , Barclays , Coherus Biosciences Inc , Eagle Bay Advisors , Princeton Global Asset Management , Get Free Report , Bay Advisors , Financial Advisors , Global Asset Management , Whitney Trust , Federated Hermes , Coherus Biosciences Daily , Nasdaq Chrs , Chrs , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.